LOAD MORE
You're viewed all 17 products
Isomeric impurities in Ibrutinib occur due to the presence of stereoisomers during the synthetic process.
Degradant impurities in Ibrutinib result from the breakdown of the drug substance due to factors such as hydrolysis, oxidation, or photolysis.
The residual solvents in Ibrutinib are the solvents used during the synthetic process but remain in the final product in small amounts.
The impurities in Ibrutinib are identified and characterized through analytical methods such as liquid chromatography-mass spectrometry (LC-MS), etc.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.